[go: up one dir, main page]

LV11103A - Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai - Google Patents

Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai

Info

Publication number
LV11103A
LV11103A LV930567A LV930567A LV11103A LV 11103 A LV11103 A LV 11103A LV 930567 A LV930567 A LV 930567A LV 930567 A LV930567 A LV 930567A LV 11103 A LV11103 A LV 11103A
Authority
LV
Latvia
Prior art keywords
weight
pct
parts
dofamina
nervous system
Prior art date
Application number
LV930567A
Other languages
English (en)
Other versions
LV11103B (en
Inventor
Udo Wenzel
Guenther Weber
Juergen Metzner
Alfred Darr
Sabine Freitag
Frank-Ulrich Floether
Frank-Michael Albert
Margit Haase
Edith Leistner
Original Assignee
Isis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh
Publication of LV11103A publication Critical patent/LV11103A/lv
Publication of LV11103B publication Critical patent/LV11103B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-93-567A 1991-01-23 1993-06-14 Oraly administerable drugs for the treatment of central dopamine deficiency conditions LV11103B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4101873A DE4101873C2 (de) 1991-01-23 1991-01-23 Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (de) 1991-01-23 1992-01-23 Peroral applizierbare arzneiform zur behandlung zentraler dopaminmangelzustände

Publications (2)

Publication Number Publication Date
LV11103A true LV11103A (lv) 1996-04-20
LV11103B LV11103B (en) 1996-06-20

Family

ID=6423528

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-567A LV11103B (en) 1991-01-23 1993-06-14 Oraly administerable drugs for the treatment of central dopamine deficiency conditions

Country Status (22)

Country Link
US (1) US5532274A (lv)
EP (1) EP0568577B1 (lv)
JP (1) JP3382940B2 (lv)
AT (1) ATE147264T1 (lv)
AU (1) AU658171B2 (lv)
BG (1) BG61677B1 (lv)
CA (1) CA2101164C (lv)
CZ (1) CZ280847B6 (lv)
DE (2) DE4101873C2 (lv)
DK (1) DK0568577T3 (lv)
EE (1) EE03016B1 (lv)
ES (1) ES2098496T3 (lv)
FI (1) FI101040B (lv)
GR (1) GR3022993T3 (lv)
LT (1) LT3659B (lv)
LV (1) LV11103B (lv)
NO (1) NO304638B1 (lv)
RO (1) RO114737B1 (lv)
RU (1) RU2114619C1 (lv)
SK (1) SK278736B6 (lv)
UA (1) UA27848C2 (lv)
WO (1) WO1992012710A1 (lv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
RU2173150C1 (ru) * 2000-06-27 2001-09-10 Васильев Виталий Николаевич Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
CN100408029C (zh) * 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
MXPA06002344A (es) 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
PT1751087E (pt) * 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
CN101141949B (zh) * 2005-03-28 2010-12-08 奥瑞克索股份公司 用于治疗帕金森病的药物组合物
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CN101910113A (zh) 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
EP2233131A1 (en) * 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) * 2018-11-13 2020-05-20 日本酢ビ・ポバール株式会社 結合剤
EP3881838A4 (en) * 2018-11-13 2022-08-17 Japan Vam & Poval Co., Ltd. ADHESIVE
US12378398B2 (en) * 2018-11-13 2025-08-05 Japan Vam & Poval Co., Ltd. Binder
WO2020100933A1 (ja) * 2018-11-13 2020-05-22 日本酢ビ・ポバール株式会社 結合剤
EP4134103A4 (en) * 2020-04-10 2024-04-24 Japan Vam & Poval Co., Ltd. BINDER
JP7569866B2 (ja) * 2020-11-19 2024-10-18 旭化成株式会社 多孔質膜
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE631201C (de) * 1932-08-07 1936-06-16 Chemische Forschungs Gmbh Traegerstoff fuer Arzneimittel
DE748317C (de) * 1941-08-17 1944-12-19 Wacker Chemie Gmbh Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) * 1967-08-31 1971-06-08 Eisai Co Ltd Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) * 1968-10-01 1976-05-17 Merck & Co Inc Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en) 1979-04-26 1985-10-16 Merrell Toraude & Co Alpha-halomethylaminoacids
DE3042916A1 (de) * 1979-06-01 1982-07-01 Joachim 7440 Nürtingen Dudzik Tablette
CA1218604A (en) * 1981-07-08 1987-03-03 Alec D. Keith Trinitroglycerol sustained release vehicles and preparations therefrom
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
EP0147780A3 (en) * 1984-01-03 1987-03-11 Merck & Co. Inc. Drug delivery device
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
ZA889189B (en) * 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
AU608891B2 (en) * 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
ES2052681T5 (es) * 1987-12-31 1997-12-01 Asta Medica Ag Combinacion sinergica de inhibidores de descarboxilasa y granulos de l-dopa.

Also Published As

Publication number Publication date
FI101040B (fi) 1998-04-15
WO1992012710A1 (de) 1992-08-06
CZ369292A3 (en) 1993-09-15
JP3382940B2 (ja) 2003-03-04
CA2101164C (fr) 2001-04-24
EP0568577B1 (de) 1997-01-08
NO932522L (no) 1993-07-09
CZ280847B6 (cs) 1996-04-17
FI933304L (fi) 1993-07-22
DK0568577T3 (da) 1997-06-30
LT3659B (en) 1996-01-25
BG97894A (bg) 1994-04-29
FI933304A0 (fi) 1993-07-22
ES2098496T3 (es) 1997-05-01
CA2101164A1 (fr) 1992-07-24
ATE147264T1 (de) 1997-01-15
UA27848C2 (uk) 2000-10-16
GR3022993T3 (en) 1997-07-30
DE59207852D1 (de) 1997-02-20
LV11103B (en) 1996-06-20
BG61677B1 (bg) 1998-03-31
NO932522D0 (no) 1993-07-09
DE4101873C2 (de) 1993-12-09
JPH06504543A (ja) 1994-05-26
EE03016B1 (et) 1997-08-15
RO114737B1 (ro) 1999-07-30
LTIP555A (en) 1994-11-25
RU2114619C1 (ru) 1998-07-10
AU658171B2 (en) 1995-04-06
SK369292A3 (en) 1998-02-04
NO304638B1 (no) 1999-01-25
EP0568577A1 (de) 1993-11-10
AU1186892A (en) 1992-08-27
SK278736B6 (sk) 1998-02-04
US5532274A (en) 1996-07-02
DE4101873A1 (de) 1992-07-30

Similar Documents

Publication Publication Date Title
LV11103A (lv) Perorali lietojama zalu forma centralas nervu sistemas dofamina deficita stavoklu arstesanai
AP9600868A0 (en) Polymer coated tablet comprising amoxycillin and clavulanate.
DK1348429T3 (da) Smelteekstruderede opioidformuleringer, der kan administreres oralt
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
IL117356A0 (en) Controlled release pharmaceutical composition for oral administration
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
ATE315399T1 (de) Hemmung von systemischen infektionen in menschen und wirbeltieren mit ballaststoffen
KR970025615A (ko) 암 전이 억제제
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
US5082665A (en) Anti-snoring formulations using yohimbine
FI955837A0 (fi) Menetelmä suun kautta annettavan, kiinteän, diklofenaakkia sisältävän annostelumuodon valmistamiseksi
KR890007728A (ko) 진통제 제조방법
IT1224250B (it) Associzione del depiprazolo con la morfina
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
HUP0103864A2 (hu) 3-(1H-4-Imidazolimetil)-indan-5-ol alkalmazása intraspinálisan beadható gyógyszerkészítmények előállítására
KR930700100A (ko) 수의학적 치료
RU2002112882A (ru) Способ повышения резистентности сухостойных коров
MX9605055A (es) Tableta revestida de polimero que comprende amoxicilina y clavulanato.
ES2093515T3 (es) Aplicacion del riluzol como radio-restaurador.